15 results about "Serum plasma" patented technology

The application discloses a red blood cell alloantibody specificity analysis method, and aims at the defects in the prior art that a large amount of manual experience and subjective judgment are relied on to exclude positive antigens according to the results of non-agglutination of samples to be detected and cells, and scientific methods such as statistics are lacked to verify the reliability of detection results, and provides a red blood cell alloantibody specificity analysis method. According to the expression of red blood cell antigens of spectrum cells / anti-screen cells and the agglutination results of patient serum / plasma, the red blood cell alloantibody specificity is analyzed by using programmed analysis logic and statistical result analysis.

A method for the extraction and enrichment of Hepatitis C Virus (HCV) antigens by conjugating specific antibodies targeting Envelope 1, Envelope 2, NS3, and NS4 antigens to a temperature-responsive smart polymer (NIPAAm-Co-HIPAAm-Co-SAKIPAAm). The application also relates to a detection kit for HCV antigens, comprising the smart polymer conjugated to specific antibodies, colloidal gold nanoparticles conjugated to specific antibodies, and instructions for detecting HCV antigens in serum, plasma, or whole blood samples.

The application discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting the curative effect of esophageal squamous cell carcinoma immunotherapy, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. The reagent for detecting indole-3-lactic acid concentration is aimed at samples selected from serum, plasma, blood, tumor tissue or fecal samples. By establishing a prediction model for the curative effect of esophageal squamous cell carcinoma immunotherapy, the curative effect of immunotherapy on esophageal squamous cell carcinoma patients can be accurately predicted, valuable reference bases can be provided for clinicians, thus helping to formulate individualized immunotherapy strategies and improving the curative effect of immunotherapy.

The application discloses a platelet antibody detection and cross matching blocking chromatography kit and a detection method thereof, wherein the kit comprises a U-shaped microwell plate, a chromatography medium for separating platelet immune complexes from non-cell particle components under the action of centrifugal force, freeze-dried platelets, a platelet diluent, a platelet fluorescent staining solution comprising fluoresceinized platelet antibodies specifically labeled for platelets, biotin-labeled anti-human globulin for specifically binding with antibodies bound to the surface of the platelets, avidinized fluorescein for coupling with the biotin-labeled anti-human globulin through a biotin-avidin specific binding system, negative control serum / plasma and positive control serum / plasma. The application combines the blocking chromatography technology with a high-sensitivity flow immunofluorescence method to construct an efficient and accurate platelet antibody detection and cross matching system, which is high in specificity and sensitivity, simple in operation and stable in detection results.

The invention relates to the technical field of medical examination, and provides a detection tube for serum / plasma insufficiency samples, which comprises a blood collection tube, the top of the blood collection tube is fixedly connected with a tube opening convex edge, the top end of the blood collection tube is provided with a detection tube fitting, the detection tube fitting comprises a lower tube and an upper tube, the inner side of the upper tube is provided with a clamping groove in sliding fit with the tube opening convex edge, and the upper tube is provided with a clamping groove. An aluminum film adheres to the top of the upper-section pipe, a liquid pumping hose is fixedly connected to the bottom of the lower-section pipe, a one-way valve is fixedly connected to the liquid pumping hose, and a negative pressure piece which abuts against the pipe opening convex edge to pump out gas in the upper-section pipe to enable the upper-section pipe to generate negative pressure is arranged on the inner side of the clamping groove. A plurality of positioning pieces which are in sliding fit with the outer wall of the convex edge of the pipe orifice are arranged on the outer side of the upper-section pipe and are distributed around the upper-section pipe at equal angles. Through intelligent design and component optimization, the detection feasibility of the serum / plasma insufficiency sample is remarkably improved, and the progress of the medical examination technology is promoted.

This invention provides a material for detecting serum plasma anti-nicotinic acetylcholine receptor antibodies and its method of use. The material comprises HEK293T cells transfected with three recombinant expression plasmids: the first plasmid encodes a truncated AChR α subunit; the second plasmid is a polycistronic plasmid encoding a fusion protein composed of a truncated AChR β subunit, an AChR δ subunit, and rapsyn protein linked by a P2A peptide; and the third plasmid encodes a truncated AChR γ subunit or ε subunit. After co-transfection with PEI, the cells are cultured in fresh complete medium for 25-35 hours after 7-9 hours post-transfection, followed by fixation, blocking, and preservation. This invention, through a three-plasmid system and antigen truncation modification, reduces cytotoxicity while ensuring high expression of the functional pentamer, significantly improving detection sensitivity and reagent shelf life.

The invention discloses application of a reagent for detecting ILA concentration in preparation of a product for predicting esophageal squamous cell carcinoma immunotherapy curative effect, a prediction method and equipment, and relates to the technical field of immunotherapy curative effect prediction. A sample targeted by the reagent for detecting the concentration of indole-3-lactic acid is selected from serum, plasma, blood, tumor tissue or a fecal sample. By establishing the prediction model for the curative effect of the esophageal squamous cell carcinoma immunotherapy, the immunotherapy effect of a patient with the esophageal squamous cell carcinoma can be accurately predicted, and valuable reference bases can be provided for clinicians, so that making of personalized immunotherapy strategies is facilitated, and the effect of the immunotherapy is improved.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention discloses a novel amplification-free ultra-sensitive protein detection method and kit based on lanthanide MOF, and belongs to the technical field of protein detection and biosensing. According to the method, the lanthanide MOF material is specifically combined with the charge complementation of the target protein, and is combined with the signal amplification effect of the ssDNA of the labeled fluorophore and phosphate, so that the rapid quantitative detection of the low-abundance protein in the biological sample is realized. The kit comprises a lanthanide MOF material, ssDNA marked with fluorophores, a phosphate buffer solution, a target protein standard substance and the like. An enzyme or nucleic acid amplification step is not needed, the detection limit is as low as 1pg / mL, and compared with an ELISA method, the sensitivity gt is improved; the detection time is shortened to 1-2 h, the detection cost is only 1 / 16 of that of ELISA, and the kit is suitable for detection of protein markers in various biological samples such as serum, plasma and urine and can be widely applied to scenes such as early diagnosis of diseases, precise medical treatment and environmental monitoring.

The invention discloses a chemiluminescence immunoassay determination kit for detecting colloidal fibrillary acidic protein in a whole blood sample and a preparation method thereof, the determination kit comprises an R1 reagent which is streptavidin-coated magnetic particles, an R3 reagent which is an acridinium ester-labeled GFAP monoclonal antibody, and an R4 reagent which is a biotin-labeled GFAP monoclonal antibody, the reagent R3 and the reagent R4 are dissolved in a diluent, the diluent is a citric acid buffer solution containing a defoaming agent adapted to a whole blood sample system, and the defoaming agent is polydimethylsiloxane. A whole blood sample can be directly detected on a machine after being collected, separation treatment of serum and plasma is not needed, and the problems that in traditional serum and plasma sample detection, sample treatment time is long, and the detection turnover period is long can be effectively solved; meanwhile, the defoaming agent is added to prevent the formation of a bubble-protein compound, so that the detection precision of the reagent is remarkably improved.

The present invention provides methods for using pre-operative bodily fluid as a source for a tumor reference genome. In some embodiments, the pre-operative bodily fluid is sequenced to identify a genomic variant specific to a tumor. In some embodiments, assays are performed to detect the presence of the genomic variant specific to a tumor identified in the pre-operative bodily fluid in surgical drain fluid. In some embodiments, the bodily fluids may be blood, urine, serum, plasma, saliva, sweat, milk, mucous, semen, vaginal or urethral secretions, cerebrospinal fluid, or surgical lavage fluid.

The invention provides a high-stability anti-ganglioside antibody detection membrane strip and a kit comprising the same, and belongs to the technical field of biological detection. The detection membrane strip comprises a carrier membrane and a ganglioside antigen coated on the surface of the carrier membrane, the surface of the carrier membrane is combined with the antigen through a thiol-Schiff base double-dynamic covalent network, and the network is composed of a Schiff base bond formed by a carrier membrane aldehyde group and an antigen sugar chain amino group, and a disulfide bond formed by a carrier membrane thiol group and an antigen lipid tail thiol group. The directional fixation of the antigen can be realized, and the dynamic repair capability is realized; a cascade anti-oxidation system is embedded into the network, so that the antigen stability is synergistically improved. The kit containing the membrane strip can be used for detecting the anti-ganglioside antibody in serum, plasma or cerebrospinal fluid, and solves the problems of short period of validity, large batch difference and the like caused by the fact that an existing detection membrane strip is easy to oxidize antigens and poor in coating stability.

The invention relates to the technical field of detection kits, and provides an oxidized low-density lipoprotein colloidal gold immunochromatography detection kit. According to the kit for detecting the oxidized low-density lipoprotein, the oxidized low-density lipoprotein in serum, plasma and whole blood can be detected at the same time, treatment modes such as centrifugation and the like do not need to be carried out on a blood sample, and the detection time is greatly shortened; the kit has the advantages of high sensitivity, high repeatability, high specificity, wide linear range, low cost and the like, has the advantages of convenience in operation and detection while arrival of POCT (point-of-care testing) rapid diagnosis, and saves precious time for bedside detection, remote mountainous area and community detection and emergency treatment detection.

This invention discloses a Mycoplasma pneumoniae antibody detection kit based on immunoturbidimetry, belonging to the field of clinical immunology testing. It includes solutions R1 and R2. Solution R1 is a dispersion of double-coupled latex microspheres coated with natural Mycoplasma pneumoniae antigens, and solution R2 is a sample diluent containing an enhancer. The test samples can be serum, plasma, or whole blood samples, and it is applicable to biochemical analyzers, protein analyzers, or combined blood cell and immunoturbidimetric analyzers. The kit prepared by this invention can be used on various instruments, has a wide range of detection targets, and can be coupled with other instruments to detect various clinically valuable blood indicators, further shortening the testing time. It solves the problems of poor accuracy, low efficiency, and limited application scenarios caused by the subjective interpretation of results, long processing time, and limited applicability of blood samples in existing technologies. It can effectively simplify the testing process and improve diagnostic efficiency.

A retrotransposable element based multiplexed qPCR assay to robustly quantitate and distinguish cell free DNA integrity and concentration in blood plasma and serum is described. The multiplexed system for characterizing cancer in humans includes a sample of serum, plasma, urine, or other biological fluid, the sample comprising cell free DNA, the cell free DNA comprising long and short retrotransposable element targets and an added internal positive control, the long and short targets being independent of each other, a distinctly labeled TaqMan probe corresponding to each target, a forward primer and a reverse primer corresponding to each target, a DNA standard for generating standard curves, a qPCR system for amplifying the targets and a qPCR data analysis system. The assay provides an accurate, minimally-invasive, rapid, high-throughput, and cost-effective method with the potential to complement or replace existing methods for detection, diagnosis, prognosis, treatment monitoring and / or surveillance of cancer, thereby improving patient outcomes.